HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.

doi:10.3851/IMP2938

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.

Antiviral therapy - 1 Jan 2015

Gomes-Gouvêa Michele S, Ferreira Ariana C, Teixeira Rosangela, Andrade José R, Ferreira Adalgisa S P, Barros Lena M F, Rezende Rosamar E F, Nastri Ana C S Santos, Leite Andrea G B, Piccoli Leonora Z, Galvan Josiane, Conde Simone R S S, Soares Manoel C P, Kliemann Dimas A, Bertolini Dennis A, Kunyoshi Aline S O, Lyra André C, Oikawa Marcio K, de Araújo Luciano V, Carrilho Flair J, Mendes-Corrêa Maria C J, Pinho João R Rebello

Abstract excerpt

BACKGROUND: Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also alter the hepatitis B surface (HBs) protein and in some cases reduce binding to HBs antibodies....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Products, pol

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B Surface Antigens

Share to Lamivudine

Share to Organophosphonates

Share to Tenofovir

Source

Open in PubMed

Identifiers

PMID: 25624410
DOI: 10.3851/IMP2938

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.PMID 25624410Read ↗

Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.Semantic proximity Read ↗

Mutations in Pol gene of hepatitis B virus in patients with chronic hepatitis B before and after therapy with nucleoside/nucleotide analogues.Semantic proximity Read ↗

Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/ nucleotide analogue treatment among Chinese chronic hepatitis B patientsSemantic proximity Read ↗

Treatment for hepatitis B in patients with drug resistanceSemantic proximity Read ↗

Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States.Semantic proximity Read ↗

Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis BSemantic proximity Read ↗

[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].Semantic proximity Read ↗

Antiviral Resistance Mutations and Genotype-Associated Amino Acid Substitutions in Treatment-Naïve Hepatitis B Virus-Infected Individuals from the Indian SubcontinentSemantic proximity Read ↗

Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.Semantic proximity Read ↗

Antiviral drug resistance and hepatitis B: a continuing public health problem.Semantic proximity Read ↗

Characterization of mutations in the reverse transcriptase region of hepatitis B virus in treated and untreated chronic hepatitis B patients.Semantic proximity Read ↗

Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.